

A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI

Submission date 22/08/2013	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 22/08/2013	Overall study status Completed	☐ Statistical analysis plan
		☒ Results
Last Edited 19/08/2019	Condition category Nervous System Diseases	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Miss Ailsa Weatherall

Contact details
Clinical Research Centre
Royal London Hospital
2 Newark Street
London
United Kingdom
E1 2AT
-
ailsa.weatherall@bartshealth.nhs.uk

Additional identifiers

ClinicalTrials.gov (NCT)
NCT01767701

Clinical Trials Information System (CTIS)

2012-004847-61

Protocol serial number

14731

Study information

Scientific Title

A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI

Acronym

INSPIRE: Raltegravir in Relapsing MS

Study objectives

This exploratory study will enrol patients with active MS lesions will be enrolled in a baseline versus treatment clinical trial where they will be observed for 3 months, having monthly Gd-enhanced brain MRI, blood, saliva and urine collection and neurological assessments and then treated with active open-label raltegravir (400mg twice daily) and followed up with monthly Gd-enhanced brain MRI, blood, saliva and urine collection and neurological assessments for a further for 3 months.

Ethics approval required

Old ethics approval format

Ethics approval(s)

12/EE/0544; First MREC approval date 10/01/2013

Primary study design

Interventional

Study design

Non-randomised; Interventional; Design type: Not specified, Treatment

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Neurological; Subtopic: Neurological (all Subtopics); Disease: Nervous system disorders

Interventions

Raltegravir, open-label raltegravir 400mg twice daily; Follow Up Length: 6 month(s); Study Entry : Registration only

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Raltegravir

Primary outcome(s)

Gadolinium enhanced MRI; Timepoint(s): MRI every 4 weeks from day 0 to day 168

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/01/2014

Eligibility

Key inclusion criteria

1. Patients between 18-55 years of age.
2. Diagnosis of MS, according to the revised McDonald Criteria 2010.
3. EDSS score of 0-6.0 inclusive.
4. Documented at least one relapse within the past 12 months or at least one Gd-enhanced lesion on the brain MRI detected within 3 months prior to screening date.
5. Gd-enhanced lesion on screening MRI if MRI not used to meet screening criteria above.
6. Female patients of childbearing potential will be expected to be on appropriate contraception (hormonal or barrier method of birth control; abstinence) from time of consent until 6 weeks after treatment discontinuation. (the repeated administration of gadolinium and MRI are not recommended during pregnancy). NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal.
7. Females of childbearing potential must have a negative urine pregnancy test prior to every MRI scan/ within 7 days prior to being registered for protocol therapy.
8. Must give written informed consent and authorize the release and use of protected health information, as required by local law.
9. Able and willing to undergo blood, saliva and urine sampling at regular intervals as defined by the protocol.
10. Able and willing to receive Gadolinium enhanced MRIs at regular intervals as defined by the protocol.
11. Able to comply with study requirements.

Target Gender: Male & Female; Upper Age Limit 55 years ; Lower Age Limit 18 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Upper age limit

55 Years

Sex

All

Total final enrolment

31

Key exclusion criteria

1. Pregnant or breastfeeding or unwilling to use contraception.
2. Treatment with immunosuppressive, immunomodulatory or experimental treatments within the last 6 months of enrolment in the study, but excluding pulsed intravenous or oral steroids for treatment of MS relapse.
3. No pulsed intravenous or oral steroids in the 30 days preceding the baseline assessment.
4. Patients presenting with medical disorder deemed severe or unstable by the CI such as poorly controlled diabetes or arterial hypertension, severe cardiac insufficiency, unstable ischemic heart disease, abnormal liver function tests (>2.5 times ULN) and abnormal complete blood count (in particular leukopenia, as defined by a lymphocyte count <500, neutrophil <1.5 or platelet count < 100, or thrombocytopenia < 1.5 LLN), or any medical condition which, in the opinion of the chief investigator, would pose additional risk to the patient.
5. Presence of human immunodeficiency virus antibodies.
6. Patients receiving proton pump inhibitors (e.g. omeprazole/esomeprazole)
7. Patients with active hepatitis B or/and C with liver function tests >2.5 times ULN.
8. Exposure to any other investigational drug within 30 days of enrolment in the study.
9. Prior history of malignancy unless an exception is granted by the Chief Investigator.
10. History of uncontrolled drug or alcohol abuse within 6 months prior to enrolment into the study.
11. Patients treated with Rifampicin in past four weeks.

Date of first enrolment

30/04/2013

Date of final enrolment

31/01/2014

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Clinical Research Centre
London
United Kingdom
E1 2AT

Sponsor information

Organisation

Queen Mary University of London (UK)

ROR

<https://ror.org/026zzn846>

Funder(s)

Funder type

Industry

Funder Name

Merck Sharp & Dohme Ltd. (MSD) (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results			21/06/2019	No	No
Basic results			19/08/2019	No	No
HRA research summary			28/06/2023	No	No